FUJIFILM Diosynth Biotechnologies, a world-leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, announced an expansion of its single-use manufacturing campus in College Station through the addition of a new cGMP production facility that will double the Company’s advanced therapy and vaccine manufacturing capacity in the U.S.
Read the full article:
FUJIFILM Diosynth Biotechnologies to Increase Advanced Therapy and Vaccine Production Capacity with New $300 Million Facility in Texas